Disturbance of gene expression in endometrial cancer as therapy aim;Zaburzenia ekspresji genów w raku endometrium jako cel terapii

Ginekologia Polska

Volumn 82, Issue 4, 2011, Pages 276-280

  Patrycja, Grosman Dziewiszek ^a   Piotr, Dziegiel ^a,b,c   Maciej, Zabel ^a,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Chemotherapy; Combined therapy; Endometrial cancer; Gene expression; Monotherapy

Indexed keywords

EID: 79960351817     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Ferlay J, Shin H, Bray F, [et al.]. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900
2. Krajowy Rejestr Nowotworow. Wspołczynniki standaryzowane dla zachorowań w podziale na rozpoznania. 2008. http://85.128.14.124/krn/std_zach/default.asp
3. Amant F, Moerman P, Neven P, [et al.]. Endometrial cancer. Lancet. 2005, 366, 491-505.
4. Korczyński J, Gottwald L, Gora E, Bieńkiewicz A. Rak trzonu macicy u kobiet po 65. Roku życia. Analiza kliniczna i patomorfologiczna. Przegla{ogonek}d Menopauzalny. 2006, 4, 213-217.
5. Catalano S, Giordano C, Rizza P, [et al.]. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol. 2009, 218, 490-500.
6. Klemba A, Kukwa W, Bartnik E, [i wsp.]. Biologia molekularna i diagnostyka raka endometrium. Post Hig Med Dosw. 2008, 62, 420-432.
7. Gabryś M. Epidemiologia i etiopatogeneza raka błony śluzowej trzonu macicy. W: Ginekologia Onkologiczna. Red. Markowska J., Wrocław: Elsevier Urban & Partner. 2006, Tom II, 683-692.
8. Engelsen I, Akslen L, Salvesen H. Biologic markers in endometrial cancer treatment. APMIS. 2009, 117, 693-707.
9. Doll A, Abal M, Rigau M, [et al.]. Novel molecular profiles of endometrial cancer - new light through old windows. J Steroid Biochem Mol Biol. 2008, 108, 221-229.
10. Kaźmierczak W. Rak endometrium - aspekty hormolane. Ginekologia Praktyczna. 2004, 12, 13-16.
11. Guirguis A, Elishaev E, Oh S, [et al.]. Use of gene expression profiles to stage concurrent endometroid tumors of the endometrium and ovary. Gynecol Oncol. 2008, 108, 370-376.
12. Zorn K, Bonome T, Gangi L, [et al.]. Gene expression profiles of serous, endometroid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005, 11, 6422-6430.
13. Horn LC, Meinel A, Handzel R, Einenkel J. Histopathology of endometrial hyperplasia and endometrial carcinoma. an update. Ann Diagn Pathol. 2007, 11, 297-311.
14. Kounelis S, Kapranos N, Kouri E, [at al.]. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2000, 13, 379-388.
15. Zagouri F, Bozas G, Kafantari E, [et al.]. Endometrial cancer: what is new in adjuvant and molecular targeted therapy? Obstet Gynecol Int. 2010, 2010, 74959.
16. Zhou C, Bae-Jump V, Whang Y, [et al.]. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol. 2006, 101, 305-310.
17. Kapucuoglu N, Aktepe F, Kaya H, [et al.]. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007, 203, 153-162.
18. Mutter G, Lin M, Fitzgerald J, [et al.]. Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers. J Natl Cancer Inst. 2000, 92, 924-931.
19. Vilgelm A, Lian Z, Wang H, [et al.]. Akt-mediated phosphorylation and activation of estrogen receptor alfa is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res. 2006, 66, 3375-3380.
20. Nagata Y, Lan K, Zhou X, [et al.]. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Res. 2004, 6, 117-127.
21. Blanco-Aparicio C, Renner O, Leal J, Carnero A. PTEN, more than AKT pathway. Carcinogenesis. 2007, 28, 1379-1386.
22. Temkin S, Yamada S, Fleming G. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010, 117, 473-476.
23. Dizon D. Treatment options for advanced endometrial carcinoma. Gynecol Oncol 2010; 117: 373-381
24. Gadducci A, Cosio S, Genazzani A. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal Therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006, 58, 242-256.
25. Sehouli J, Koensgen D, Oska-Ozcelik G, Mustea A. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Crit Rev Oncol Hematol. 2008, 67, 204-212.
26. Slomovitz B, Lu K, Johnston T, [et al.]. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010, 116, 5415-5419.
27. Colombo N, McMeekin S, Schwartz P, [et al.]. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2007, 25, 5516.
28. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 200, 319, 1-11.
29. Sugimoto T, Koizumi T, Sudo T, [et al.]. Correlative expression of cyclooksygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer. Kobe J Med Sci. 2007, 53, 177-187.
30. Li Y, Pan Y, Wei Y, [et al.]. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004, 6, 459-469.
31. Montejo M, Werner T, Gaffney D. Current challenges in clinical management of endometrial cancer. Adv Drug Deliv Rev. 2009, 61, 883-889.
32. Fleming F, Sill M, Darcy K, [et al.]. Phase II Trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010, 116, 15-20.
33. Hu X, Su F, Qin L, [et al.]. Stable RNA interference of ErbB-2 gene synergistic with epirubicin supresses breast cancer growth in vitro and in vivo. Biochem Biophys Res Commun. 2006, 346, 778-785.
34. Wang S, Lien H, Xia W, [et al.]. Binding et and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB2. Cancer Cell. 2004, 6, 251-261.
35. Fujiwaki R, Iida K, Kanasaki H, [et al.]. Cyclooksygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosporylase. Hum Pathol. 2002, 33, 213-219.
36. Ferrandina G, Ranelletti F, Gallotta V, [et al.]. Expression of cyclooksygenase-2 (COX-2), receptors for estrogen (ER) and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005, 98, 383-389.
37. Gao J, Tian J, Lv Y, [at al.]. Leptin induces functional actvation of cyclooksygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2008, 100, 389-395.
38. Collins F, Mac PhersonSh, Brown P, [et al.]. Expression of oestrogen receptors, ERalfa, ERbeta, end ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalfa. BMC Cancer. 2009, 9, 330-343.
39. Raspollini M, Susini T, Taddei G. Expression of metalloproteinases 2 and 9 and cyclooxygenase 2 in endometrial carcinoma Int J Gynaecol Obstet. 2006, 93, 64-66.
40. Viswanathan A, Feskanich D, Schernhammer E, Hankinson S. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008, 68, 2507.
41. Martinez-Campa C, Gonzalez A, Mediavilla M, [et al.]. Melatonin inhibits aromatase promoter expression by regulating cyclooksygenases expression and activity in breast cancer cells. Br J Cancer. 2009, 101, 1613-1619.
42. St-Germain M, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer. 2004, 3, 7.
43. Michalski B. Celowana terapia antyangiogenna. W: Ginekologia Onkologiczna. Red. Markowska J. Wrocław: Elsevier Urban & Partner. 2006, Tom I, 302-311.
44. Stefansson I, Salvesen H, Akslen L. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res. 2006, 66, 3303-3309.
45. Caprini D, Karam A, Montgomery L. Vascular endothelial growth factor and its relatioship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010, 13, 43-58.
46. Dobrzycka B, Terlikowski S, Kwiatkowski M, [et al]. Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer. Ginekol Pol. 2010, 81, 422-425.
47. Szmit S, Opolski G, Szczylik C. Powikłania kardiologiczne jako powikłania terapii celowanych. Współczesna Onkologia. 2008, 12, 318-323.